AMIDROX

Informazioni principali

  • Nome commerciale:
  • AMIDROX INFUS 1F 10ML 3MG/ML
  • Forma farmaceutica:
  • PREPARAZIONE INIETTABILE
  • Composizione:
  • "3MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE" 1 FIALA DA 10 ML
  • Classe:
  • H
  • Tipo di ricetta:
  • Uso ospedaliero
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco allopatico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • AMIDROX INFUS 1F 10ML 3MG/ML
    Italia
  • Lingua:
  • italiano

Altre informazioni

Status

  • Fonte:
  • AIFA - Agenzia Italiana del Farmaco
  • Numero dell'autorizzazione:
  • 036552040
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

28-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to collaborate with internet stakeholders to stop the illegal sale of opioids online

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to collaborate with internet stakeholders to stop the illegal sale of opioids online

FDA’s efforts to collaborate with internet stakeholders to stop the illegal sale of opioids online

FDA - U.S. Food and Drug Administration

28-3-2018

DKMA Update March 2018

DKMA Update March 2018

In this issue of DKMA Update you can read about evidence; changes to Tramadol’s summary of product characteristics; inspections of the sale of OTC medicines outside pharmacies and much more

Danish Medicines Agency

8-6-2016

Beware of falsified medicines

Beware of falsified medicines

Today, 8 June 2016, is the World Anti-Counterfeiting Day. The Danish Medicines Agency participates in this campaign to draw attention to the problem of illegal sale of falsified medicines.

Danish Medicines Agency

28-5-2014

More than 10,000 websites shut down in global operation

More than 10,000 websites shut down in global operation

The recent global Operation PANGEA VII resulted in the shutdown of more than 10,000 websites. The operation focused on combating online sale of counterfeit medicines and making consumers aware that they need to take care of themselves when buying medicines online. Globally, the operation led to 237 arrests, some 540,000 parcels were inspected and over 9.4 million units containing potentially life-threatening medicines were seized – worth an estimated value of more than USD 35 million. More than 10,000 we...

Danish Medicines Agency

21-4-2006

Warning: Sale of illegal diet pills

Warning: Sale of illegal diet pills

Illegal diet pills containing the active substances ephedrine and ephedra are sold in a number of shops and on the internet. The illegal products are sold under names such as Therma Power

Danish Medicines Agency

22-7-2018

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device an

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device an

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device and earlier agency actions

FDA - U.S. Food and Drug Administration